Analysts Anticipate Endocyte, Inc. (ECYT) to Post -$0.25 EPS
Brokerages expect that Endocyte, Inc. (NASDAQ:ECYT) will post earnings per share of ($0.25) for the current quarter, according to Zacks. Zero analysts have made estimates for Endocyte’s earnings, with estimates ranging from ($0.27) to ($0.22). Endocyte also posted earnings of ($0.25) per share during the same quarter last year. The firm is scheduled to announce its next earnings results on Thursday, August 3rd.
On average, analysts expect that Endocyte will report full year earnings of ($0.88) per share for the current year, with EPS estimates ranging from ($0.93) to ($0.84). For the next fiscal year, analysts expect that the company will post earnings of ($0.75) per share, with EPS estimates ranging from ($0.76) to ($0.73). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Endocyte.
Endocyte (NASDAQ:ECYT) last issued its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.01. Endocyte had a negative net margin of 59,808.57% and a negative return on equity of 29.67%. The company had revenue of $0.01 million during the quarter. During the same period in the previous year, the company posted ($0.24) earnings per share. Endocyte’s revenue was up .0% compared to the same quarter last year.
A number of brokerages recently commented on ECYT. Zacks Investment Research upgraded Endocyte from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research report on Thursday, June 8th. Wedbush lowered Endocyte from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $8.00 to $2.00 in a research report on Monday, June 5th. ValuEngine lowered Endocyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 3rd. Finally, Cowen and Company lowered Endocyte from an “outperform” rating to a “market perform” rating in a research report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $3.58.
A number of hedge funds have recently made changes to their positions in the company. Stifel Financial Corp raised its stake in shares of Endocyte by 3.9% in the first quarter. Stifel Financial Corp now owns 45,353 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,711 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Endocyte by 4.7% in the first quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock worth $369,000 after buying an additional 6,469 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of Endocyte by 17.1% in the fourth quarter. Teachers Advisors LLC now owns 65,119 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 9,506 shares during the last quarter. State Street Corp raised its stake in shares of Endocyte by 2.7% in the fourth quarter. State Street Corp now owns 620,248 shares of the biopharmaceutical company’s stock worth $1,582,000 after buying an additional 16,289 shares during the last quarter. Finally, Stoneridge Investment Partners LLC raised its stake in shares of Endocyte by 40.0% in the first quarter. Stoneridge Investment Partners LLC now owns 57,406 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 16,399 shares during the last quarter. Hedge funds and other institutional investors own 33.04% of the company’s stock.
Shares of Endocyte (ECYT) opened at 1.52 on Wednesday. The firm’s market capitalization is $64.55 million. The firm has a 50-day moving average of $2.19 and a 200-day moving average of $2.34. Endocyte has a one year low of $1.50 and a one year high of $3.53.
Endocyte Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.